The authors used an engineered hematopoietic stem cell–based platform that delivers cytokines to the tumor microenvironment to improve the efficacy of B7-homolog 3–targeting CAR T cells in an orthotopic syngeneic mouse model of glioblastoma.
[Science Translational Medicine]